On September 17, Moderna, Inc. rose 5.16% in regular trading, trading at $152.57 per share, with turnover of $104 million, extending gains from the prior session.

On the news front, a wave of institutional upgrades has fueled bullish sentiment around the stock. The rally stems from positive Phase 3 clinical results for a personalized mRNA cancer vaccine co-developed with Merck — the world's first Phase 3 positive data for this class of vaccine — prompting a broad reassessment of mRNA technology's commercial potential in oncology. Argus Research upgraded Moderna to Buy with a $180 price target, while Barclays raised its target from $48 to $125 and JPMorgan lifted its target from $40 to $77. Berenberg also more than doubled its target to $100 from $45. UBS highlighted three near-term individualized neoantigen therapy data readouts as additional catalysts, including Phase 3 melanoma data expected at an international conference this fall.

Separately, President Stephen Hoge sold 80,575 shares on September 14–15 at average prices of $144.13 and $146.07, a transaction investors may wish to monitor alongside the positive clinical developments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)